Overview

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Status:
Not yet recruiting
Trial end date:
2025-11-07
Target enrollment:
Participant gender:
Summary
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline